Introduction
The Bcl-2 family of proteins has been reported to participate in the regulation of apoptosis and, more recently, in cell growth and differentiation. Some members of the Bcl-2 family, such as Bcl-2, Bcl-X L , and Mcl-1, function as antiapoptotic proteins, whereas Bax, Bad, Bak, and Bid work as cell death promoters. 1 Among these Bcl-2 family members, Bcl-X L appears to be especially important for erythropoiesis. Several studies have revealed that Bcl-X L , but not Bcl-2, is required for the survival and normal maturation of erythroid cells. The important role of Bcl-X L in the control of erythropoiesis was first suggested by studies showing that Bcl-X Ϫ / Ϫ mouse embryos exhibit apoptosis of fetal liver hematopoiesis and pallor 2 and its up-regulation during terminal erythroid differentiation. 3 Further studies in vivo have shown that Bcl-X Ϫ / Ϫ embryonic stem (ES) cells in chimeric mice do not contribute to circulating adult definitive erythrocytes, indicating that Bcl-X L is central for full erythroid maturation. 4 Erythropoietin (EPO) allows erythroid precursors to proliferate and mature while protecting them from apoptosis. Several studies reported that EPO induces Bcl-X L in different EPO-dependent erythroid cell lines. 5, 6 The regulation of Bcl-X L function is likely to play a major role in the antiapoptotic effect of EPO. Recent reports have demonstrated that EPO-dependent activation of the factor STAT5 is probably involved in the induction of Bcl-X L expression. 7, 8 The transcriptional factor GATA-1 is also crucial for the maturation and survival of erythroid precursors and erythroblasts. 9 GATA-1 strongly induces the expression of Bcl-X L in erythroid cells and cooperates with EPO signaling in this regard. 10 So, the EPO and GATA-1 signaling pathways converge to promote erythroid cell survival through activation of Bcl-X L expression.
Findings using in vitro hematopoietic differentiation of mouse bcl-X Ϫ / Ϫ ES cells clearly indicate that Bcl-X L is essential at a late stage of erythroid maturation. 4, 10 Finally, Wagner et al have recently described the phenotypic analysis of adult mice that are conditionally deficient in the Bcl-X gene. 11 The animals suffered from severe hemolytic anemia and profound splenomegaly. Moreover, according to earlier findings in vitro, they demonstrated that Bcl-X L is only required for the survival of erythroid cells at the end of maturation, which includes enucleated reticulocytes in circulation.
Taken together, the data point to an essential role for Bcl-X L in maintaining the survival of differentiated erythroid cells. However, it remains unclear whether suppression of apoptosis is the sole function of Bcl-X L in terminal erythroid differentiation. To investigate this, we have employed the Friend murine erythroleukemia (MEL) cell model which provides a useful system for studying the mechanism of erythroid differentiation. MEL cells are erythroid precursors that are blocked at the proerythroblast stage. When exposed to dimethyl sulfoxide (DMSO) or other inducers, MEL cells undergo phenotypic changes that resemble the final stages of normal erythropoiesis, including hemoglobin synthesis. 12, 13 We have previously reported that DMSO induction of terminal erythroid differentiation in MEL cells correlates with a delay of apoptosis and a specific induction of the Bcl-X L protein. 14 Here, we have created MEL cell lines which overexpressed Bcl-2 or Bcl-X L and a variant cell line transfected with a Bcl-X L antisense construct. Our results demonstrate that Bcl-2 prevents apoptosis in differentiated MEL cells, whereas Bcl-X L only delays it. Bcl-X L antisense transcripts accelerated apoptosis in DMSO-induced MEL cells and blocked their production of hemoglobin. Furthermore, we show that an antisense oligonucleotide to Bcl-X L may block hemoglobin synthesis in MEL cells in the absence of apoptosis. Finally, heme synthesis, but not globin mRNA expression, was prevented when Bcl-X L was inhibited in MEL cells.
Materials and methods

Chemicals and antibodies
DMSO was from BDH (Poole, United Kingdom) and bovine hemin was from Sigma Aldrich (St Quentin Fallavier, France). The primary antibodies used in Western blot analysis were mouse monoclonal anti-Bcl-2 from DAKO (Trappes, France), rabbit polyclonal anti-Bcl-X from BD Transduction Laboratories (Le Pont de Claix, France), rabbit polyclonal anti-actin from Sigma Aldrich, and mouse monoclonal anti-cytochrome oxidase subunit IV from Molecular Probes (Eugene, OR).
Plasmid constructs
The Bcl-2 expression vector pSFFVbcl-2neo described by S. J. Korsmeyer 15 was kindly provided by Dr J. Bréard (INSERM Unit 461, Chatenay-Malabry, France). Human Bcl-X L cDNA was excised from its plasmid vector (gift from Dr Craig B. Thompson, Chicago, IL) 16 as a 0.8-kb EcoR1 fragment and ligated into EcoR1-digested pSFFVneo with the sense and antisense orientation. The resulting expression vectors contain the Bcl-X L sense (pSFFVbcl-X L -S) or antisense (pSFFVbcl-X L -AS) downstream of the SFFV-LTR and the neomycin gene as a selective marker.
Cell lines and transfection
MEL cells, strain 745A, and derived transfectants were grown in RPMI-1640 medium (Gibco-BRL Life Technologies, Cergy Pontoise, France) containing 10% fetal calf serum (FCS; Eurobio, Les Ulis, France). 745A cells were transfected by electroporation as previously described 17 with either the pSFFVneo plasmid (745A/Neo) or plasmid constructs. Individual cell clones were selected with 300 g/mL geneticin (G418; Gibco-BRL). Clones expressing high levels of Bcl-2 or Bcl-X L were further subcloned by limiting dilution. Representative subclones each of 745A/Neo, 745A/Bcl-2, and 745A/Bcl-X L cells were used for the studies described below. Similarly, clones transfected with pSFFVbcl-X L -AS vector that did not express Bcl-X L were subcloned and a representative subclone was selected for molecular and biologic analysis.
Benzidine staining and heme quantification
Cells were seeded at 1 ϫ 10 5 cells/mL and DMSO was added at a final concentration of 2% (vol/vol). The degree of erythroid differentiation was scored on day 4 or day 5 by counting the percentage of benzidine-positive cells as previously described. 18 In some experiments hemin was added to the medium at a final concentration of 100 M. Heme concentration in untreated and DMSO-treated cells was determined by the oxalic acidfluorometric procedure of Sassa. 19 Spectrophotometric assay for hemoglobin levels Intracellular hemoglobin levels were determined by a previously described method. 20 Briefly, cells were washed twice with phosphate-buffered saline (PBS), resuspended in 0.5 mL distilled water, and lysed by 4 cycles of freezing and thawing in a water bath at 37°C for 3 minutes. The cell lysate was centrifuged at 14 000 rpm in a microfuge for 15 minutes at 40°C. A portion of the supernatant (300 L) was transferred to a new tube. The assay mixture was prepared in duplicate by adding the reagents in the following order: 100 L supernatant, 900 L distilled water, 100 L freshly prepared benzidine-HCl (10 mg/mL in 0.5% acetic acid) and finally, 40 L of 30% H 2 O 2 . The contents were mixed well and after exactly 90 seconds the absorbance at 604 nm was measured in a spectrophotometer. Hemoglobin concentration was determined by comparing this absorbance value to a standard curve prepared by similar treatments of pure human hemoglobin solutions.
Treatment with antisense oligonucleotide to Bcl-X L
Cells were incubated for 5 days in the presence of 30 M bcl-X L antisense (AS) phosphorothioate derivatised oligodeoxynucleotide (purchased from Eurobio). Fresh oligonucleotide was added every day. Antisense DNA oligonucleotide with a phosphorothioate backbone was synthesized and purified by high-performance liquid chromatography (HPLC) (Eurobio). The antisense oligonucleotide used in this study encoded a sequence complementary to the coding region 5Ј to the translation initiation codon site for the bcl-X L gene and extending 3Ј downstream for a total of 18 bases (100% sequence identity between mouse and human). The oligonucleotide sequence used was 5Ј-CCGGTTGCTCTGAGACAT-3Ј as previously described by Pollman et al. 21 
Semiquantitative RT-PCR for globin mRNA analysis
Transcripts of ␣-and ␤-globin were analyzed by using reverse transcriptasepolymerase chain reaction (RT-PCR) as previously described. 22 Total RNA was extracted from each sample using Trizol reagent (Gibco-BRL) and cDNA was synthesized from 1 g total RNA using the Advantage RT-for-PCR Kit (Clontech, Palo Alto, CA) according to the protocol of the manufacturer. The PCR mixture was amplified by using 1 L RT reaction sample with the following primer sequences: ␣-globin (forward 5Ј-CTCTCTGGGAAGACAAAAGCAAC-3Ј, reverse 5Ј-GGTGGCTAGC-CAAGGTCACCAG-CA-3Ј), ␤-globin (forward 5Ј-CTGACAGAT-GCTCTCTTGGG-3Ј, reverse 5Ј-CACAACCCCAGAAAACAGACA-3Ј), glyceraldehyde phosphate dehydrogenase (GAPDH) (forward 5Ј-GGT-GAAGGTCGGAGTCAACGGA-3Ј, reverse 5Ј-GAGGGATCTCGCTCCT-GGAAGA-3Ј). The sequence of the primers used for the analysis of ␣-and ␤-globin expression was reported by Vannucchi et al. 23 GAPDH-specific oligonucleotides were used as the internal control. PCR conditions were as follows: 94°C for 1 minute, 55°C for 1 minute, and 72°C for 1 minute. PCR was performed at different cycle numbers to determine the linear amplification and 25 PCR cycles was the cycle number chosen to allow a linear RT-RNA dose response for the 3 genes. PCR products were electrophoresed in agarose gels and visualized by ethidium-bromide staining. Band intensities for ␣-and ␤-globin PCR products were quantitated using a densitometer (Image Quant; Molecular Dynamics) and normalized to the intensity of the GAPDH signal.
Western blot analysis
Protein lysates were separated by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), blotted onto PolyScreen membranes (NEN, Paris, France) and processed for Western blot analysis as previously described. 14 
Preparation of mitochondria and S-100 fraction
The isolation of mitochondria was adapted from a previously described method. 24 Briefly, cells were centrifuged and washed twice with ice PBS. The cell pellet was then resuspended in an ice-cold hypotonic buffer containing 10 mM NaCl, 1.5 mM MgCl 2 , and 10 mM Tris (tris(hydroxymethyl)aminomethane)-HCl, pH 7.5. After 20 minutes incubation in ice, cells were ruptured with several strokes in a Dounce homogenizer. Immediately after homogenization, the homogenate was mixed with an iso-osmotique MS buffer (final concentration 210 mM mannitol, 70 mM sucrose, 5 mM Tris-HCl, pH 7.5, and 1 mM EDTA [ethylenediaminetetraacetic acid], pH 7.5) and centrifuged at 750g for 10 minutes at 4°C to pellet nuclei and unbroken cells. The supernatant was then centrifuged at 17 000g for 15 minutes at 4°C. After washing once with MS buffer, the pellet containing mitochondria was resuspended in MS buffer and stored at Ϫ80°C. The supernatant of the 17 000g spin was further centrifuged at 100 000g for 1 hour at 4°C and the resulting supernatant (S-100) containing the cytosolic fraction was frozen at Ϫ80°C. The protein concentrations of mitochondria and S-100 were determined and 25 g protein was used for Western blot analysis of Bcl-X L .
Analysis of cell viability and apoptosis
Cells were treated by adequate stimulus and after the appropriate time, viable cells were counted using the trypan blue dye exclusion assay. The number of total and viable cells was counted every 24 hours. The percent cell viability was determined by dividing the number of viable cells by the number of total cells. Apoptosis was analyzed by staining with a mixture of ethidium bromide (EB) and acridine orange (AO). Cell suspension (25 L) was mixed with 25 L of a solution containing 500 g/mL EB and 150 g/mL AO. Cell morphology was studied using a fluorescence microscope. Live cells fluoresce green and dead cells orange. In advanced apoptosis, nuclei take the form of bright spherical beads which are distinguishable from the spheric form in necrotic cells.
Analysis of DNA fragmentation
DNA fragmentation was analyzed as previously described. 14 Briefly, 2 ϫ 10 7 cells were washed in PBS and resuspended in 50 L of 50 mM Tris-HCl, pH 8.0, 10 mM EDTA, and 0.5 mg/mL proteinase K. After incubation at 50°C for 1 hour, 1 L of 10 mg/mL RNaseA was added for an additional 1 hour at 37°C. The samples were mixed with 25 L of 10 mM EDTA, pH 8.0, containing 1% (wt/vol) low melting point agarose, 0.25% bromophenol blue, and 40% sucrose at 70°C. DNA was separated in 2% agarose gels and visualized by ultraviolet illumination after ethidium-bromide staining.
TUNEL assays
Apoptotic DNA fragments were end-labeled in situ with fluorescein-12-dUTP by terminal deoxynucleotide transferase (TdT) using the Apoptosis Detection System from Roche Diagnostics (Meylan, France). Cells were analyzed on FACScan flow cytometer (Becton Dickinson, Le Pont de Claix, France) and a total of 4000 events were collected.
Results
Establishment of stable MEL transfectants expressing Bcl-2 and Bcl-X L transcript
We have previously shown that Bcl-X L , but not Bcl-2, is expressed in Friend MEL cells. Moreover, DMSO-induced erythroid differentiation of MEL cells is associated with an enhancement of Bcl-X L expression correlated with a delay of apoptosis. 14 To investigate the potential role of these 2 antiapoptotic proteins in regulating erythroid differentiation, we introduced Bcl-2 or Bcl-X L sense expression vectors into 745A MEL cells. Cells were transfected by electroporation with linearized plasmid DNA from one of the expression vectors. 745A cells were also transfected with the control neo vector. Cells stably expressing constructs were selected by growth in G418 and 10 to 20 individual clones for each group were obtained by limiting dilution. All cellular clones were examined for their protein expression in absence of DMSO by Western blotting. A single clone that expresses high levels of Bcl-2 (745A/Bcl-2) or Bcl-X L (745A/Bcl-X L S) was used in the studies presented here ( Figure 1A ). The cell population-doubling time of 745A/Bcl-2 and 745A/Bcl-X L S cells was not significantly different from that of parental 745A or 745A/Neo cells (data not shown).
Bcl-2, but not Bcl-X L , prevents apoptosis in MEL cells before and after DMSO treatment
Cell viability was studied in both untreated 745A/Bcl-2 and 745A/Bcl-X L S cells and compared with that of 745A/Neo cells ( Figure 1B ). We noted that 745/Bcl-2 cells had a greater life span compared with that of 745A/Neo cells. All 745A/Neo cells were dead after 9 days of culture, whereas 745A/Bcl-2 cells showed 80% viability at this time. In contrast, 745A/Bcl-X L S cells only exhibited delayed spontaneous cell death compared with 745A/Neo cells and were totally dead after 9 days of culture. As seen in Figure 1B , DMSO-induced 745A/Neo cells began to die after 6 days of treatment and more than 90% were dead 10 days after DMSO treatment. The behavior of 745A/Bcl-2 cells in the presence of DMSO was clearly different from that observed in 745A/Bcl-X L S cells. DMSO-treated 745A/Bcl-X L S cells died later than DMSOtreated 745A/Neo cells but they did not survive after 10 days of treatment. In contrast, DMSO-treated 745A/Bcl-2 cells were totally resistant to death after 10 days of treatment and even after 15 days (data not shown).
These results showed that overexpression of Bcl-X L delayed but did not prevent spontaneous cell death in untreated and DMSOtreated MEL cells. In contrast, cell death was totally inhibited by overexpression of Bcl-2 in MEL cells before and after DMSO treatment. To further study cell death in MEL cells, DNA fragmentation reflecting the endonuclease activity characteristic of apoptosis was analyzed. As seen in Figure 1C , DNA fragmentation was not evident in untreated 745A/Bcl-2 cells after 5 days of culture, whereas at this time DNA genomic from 745A/Neo and 745A/Bcl-X L S cells was degraded into oligonucleosomal fragments. Similarly, after 7 days of culture with DMSO, DNA fragmentation was observed in 745A/Neo and 745A/Bcl-X L S cells but not in 745A/ Bcl-2 cells. Therefore, Bcl-2 provided better protection than Bcl-X L against apoptosis in MEL cells induced to differentiate and prevented them from apoptosis after differentiation.
Transfection with antisense Bcl-X L induces premature apoptosis in DMSO-induced MEL cells
We previously reported that DMSO treatment induced a marked increase of Bcl-X L expression correlated with a transient resistance to spontaneous apoptosis of 745A cells. 14 Incubation of MEL cells with DMSO inducer leads to the stimulation of 2 programs: one responsible for hemoglobin synthesis and the other for inhibition of cell growth. Several studies have indicated that the coordination of both programs is not obligatory. 25 That is why we examined the effect of Bcl-2 and Bcl-X L on loss of proliferative potential cell in DMSO-treated MEL cells. To study the loss of proliferative potential after DMSO induction, cells were cultured in suspension and diluted every 2 days. When MEL cells were cultured without DMSO, they grew logarithmically after each transfer. A similar growth was observed in 745A/Neo, and both 
Bcl-X L antisense oligonucleotide inhibits hemoglobin synthesis without inducing apoptosis in DMSO-treated 745A/Bcl-2 cells
Recent results suggest that Bcl-X L is necessary to maintain erythroid cell viability during normal terminal erythroid maturation. 4 
Antisense Bcl-X L inhibits heme synthesis but not globin mRNA expression in DMSO-induced MEL cells
Treatment of MEL cells with agents such as DMSO induces accumulation of ␣-and ␤-globin mRNA and heme biosynthesis leading to hemoglobin production. 13, 19, 26 We have examined the effect of antisense Bcl-X L on both globin RNA expression and heme synthesis. Globin mRNA expression was tested by semiquantitative RT-PCR ( Figure 6A 
Inhibition of hemoglobin synthesis by antisense Bcl-X L is reversed by addition of exogenous hemin
Because ␣-and ␤-globin mRNA was induced by DMSO in 745A/Bcl-X L AS cells, we investigated whether the addition of exogenous hemin can reverse the inhibition of hemoglobin synthesis. Treatment of 745A/Neo and 745A/Bcl-X L AS cells with hemin alone did not result in erythroid differentiation as measured by benzidine staining (Table 1) . However, hemin induced detectable quantities of intracellular hemoglobin in both cell lines (50 ng/10 6 cells) when hemoglobin was measured by spectrophotometry ( Figure 7) . DMSO also induced hemoglobin production in 745A/ Neo cells (110 ng/10 6 cells) but not in 745A/Bcl-X L AS cells (Figure 7 ) in agreement with results observed by benzidine staining (Table 1 and Figure 3) . When hemin was added in DMSO-treated 745A/Neo cells, the percentage of benzidine-positive cells was optimal (97%) as compared with DMSO alone (80%). After exposure to DMSO and hemin for 5 days, 45% of 745A/Bcl-X L AS cells were benzidine positive (Table 1) . Moreover, following hemin addition, DMSO-treated 745A/Bcl-X L AS cells were able to accumulate high levels of intracellular hemoglobin (280 ng/10 6 cells). These results indicated that treatment with exogenous hemin overcame the block of hemoglobin synthesis induced by Bcl-X L antisense in DMSO-treated MEL cells. These results further argued that the inhibition of Bcl-X L caused a defect in the induction of heme synthesis.
Mitochondrial localization of Bcl-X L in MEL cells after DMSO induction
To better understand the function of Bcl-X L in erythroid differentiation of MEL cells, we studied its localization before and after DMSO in parental 745A cells and in derived clones. The subcellular distribution of Bcl-X L protein was analyzed in both purified mitochondria and cytosol (Figure 8 ). Before DMSO treatment, low levels of Bcl-X L protein were found in the cytosolic fraction of 745A/Neo cells. After DMSO induction in 745A/Neo cells, Bcl-X L was induced and seen only in the mitochondria. 745A/Bcl-X L S cells expressed high levels of Bcl-X L before and after DMSO treatment. However, the protein was detected in the cytosol of untreated 745A/Bcl-X L S cells whereas, in the presence of DMSO, the protein was predominantly present in the mitochondria. These results indicate that Bcl-X L was translocated from the cytosol to the mitochondria during DMSO-induced erythroid differentiation of MEL cells.
Discussion
The relationship between cell survival and cell maturation programs remains unclear during hematopoietic differentiation. Several studies have shown that Bcl-X L is necessary for normal erythroid differentiation by maintaining survival of erythroid cells at the end of their maturation. We report here that the block of Bcl-X L during terminal erythroid differentiation of MEL cells resulted not only in premature apoptosis but also in inhibition of hemoglobin synthesis, due to a block of heme production. It is notable that the inhibition of hemoglobin synthesis by Bcl-X L antisense occurred in MEL cells even when apoptosis was overcome by Bcl-2 overexpression. We suggest that Bcl-X L has 2 independent roles in erythroid maturation: cell survival and heme synthesis.
Both Bcl-2 and Bcl-X L have been implicated in survival of erythroid progenitors but only Bcl-X L is required at the end of erythroid maturation. 4, 10, 11 A delay of apoptosis and an upregulation of Bcl-X L are found during chemical induction of MEL erythroid differentiation. 14 However, MEL cell differentiation terminates with apoptosis and high levels of Bcl-X L in MEL cells are not sufficient to protect them from apoptosis after maturation. In contrast, overexpression of Bcl-2 totally inhibits apoptosis in terminally differentiated MEL cells. These results suggest a distinction in the functional capabilities of Bcl-X L and Bcl-2 to prevent postmaturation apoptosis. There are other reports showing that Bcl-2 and Bcl-X L can differentially regulate apoptosis. 27, 28 This difference has several possible interpretations. Whereas Bcl-2 and Bcl-X L are likely to have similar tertiary structure, they may function differently by specific interactions with proteins that mediate postmaturation apoptosis. It is not known which is the proapoptotic factor that triggers apoptosis in MEL cells. We have previously reported that the proapoptotic Bax and Bad proteins are present at a high level before and after induction of differentiation in MEL cells, leaving the cells in a proapoptotic condition. 14 Although both Bcl-2 and Bcl-X L function as death repressors, Bad and Bax could differentially affect their protective ability. It has been reported that Bad interacts strongly with Bcl-X L but weakly with Bcl-2 and can overcome the antiapoptotic effect of Bcl-X L but not Bcl-2. 29 Another possibility is that agents that promote apoptosis could biochemically modify Bcl-2 or Bcl-X L . Posttranslational modification of Bcl-2 or Bcl-X L through phosphorylation has been shown to modulate their antiapoptotic activity. 30, 31 Finally, as Bcl-X L but not Bcl-2 is present in MEL cells, overexpression of Bcl-2 may lead to high levels of resistance to apoptosis due to a combination of Bcl-2 and Bcl-X L expression.
Our results indicate that the suppression of apoptosis by Bcl-2 is not sufficient to induce spontaneous erythroid differentiation in MEL cells and that DMSO induction is required to overcome the block of differentiation in this model. These results are in agreement with those reported by Chida et al, 32 showing that expression of the cell survival genes, Bcl-2 and Bcl-X L , is not sufficient for erythroid colony formation from normal erythroid colony-forming units (CFU-Es) in the absence of EPO. Moreover, targeted expression of Bcl-2 in the erythroid lineage in transgenic mice did not induce erythroid differentiation in the absence of EPO. 33 Therefore, a survival signal is probably necessary but not sufficient for induction of terminal erythroid differentiation. However, further studies using transgenic mice expressing bcl-X L gene are needed to determine whether targeted expression of Bcl-X L in the erythroid lineage would allow by itself an EPO-independent erythroid differentiation.
Several studies have indicated that survival programs are required during the initial phase of cell differentiation to escape apoptosis and complete the differentiation process. 34 Although apoptosis-resistant pathways during differentiation of leukemic cells are poorly understood, there is evidence that members of the Bcl-2 family are involved in the regulation of these processes. For example, Mcl-1 and A1, members of the Bcl-2 family, are required to prevent apoptosis during differentiation of leukemic U937 or NB4 cells. 35, 36 However, it is presently unclear whether these early survival programs are prerequisite for, occur simultaneously with, or are dependent on, cell differentiation. During the chemically induced MEL erythroid differentiation, cells must also possess a mechanism to avoid cell death until terminal differentiation occurs, allowing the development of mature cells to exhibit their functional phenotype. We have previously shown an up-regulation of Bcl-X L in MEL cells induced by DMSO or hexamethylene bisacetamide (HMBA). 14 We show here that inhibition of Bcl-X L expression by antisense transcripts or antisense oligonucleotide results in an acceleration of apoptosis in differentiating MEL cells associated with an inhibition of hemoglobin synthesis. This indicates that Bcl-X L is essential to delay apoptosis during MEL erythroid differentiation. Our results are in agreement with several studies, using different approaches, showing that Bcl-X L is required in erythroid differentiation because it protects normal erythroid cells from apoptosis during the late stages of erythroid maturation. 4, 10, 11 On the other hand, we observe that an antisense oligonucleotide to Bcl-X L does not produce apoptosis in MEL cells overexpressing Bcl-2. This indicates that Bcl-2 can overcome premature apoptosis induced by Bcl-X L inhibition in differentiating MEL cells. However, overexpression of Bcl-2 does not prevent Bcl-X L antisense oligonucleotide from inhibiting hemoglobin synthesis in DMSOtreated MEL cells. These results suggest, for the first time, that Bcl-X L has a role in hemoglobin synthesis independent of its antiapoptotic function. Thus, Bcl-X L could have a dual function during terminal erythroid differentiation, one by delaying apoptosis and allowing cells to complete the differentiation program, the other by interacting directly on hemoglobin synthesis.
Incubation of MEL cells with an inducer such as DMSO leads to the stimulation of 2 major programs: one program responsible for hemoglobin synthesis and the other for commitment to terminal maturation. 13, 25 Several studies have indicated that the coordination of these programs is not obligatory. In this study we found that, although Bcl-X L antisense transcripts affect MEL cells in their ability to synthesize hemoglobin with DMSO, they have no effect on the proliferative aspect of the erythroid differentiation. In MEL cells, both programs of differentiation, erythroid phenotypic differentiation and growth arrest, can be separately regulated. Our data show that, whereas Bcl-X L interferes with erythroid differentiation, it is not involved in terminal cell division. Terminal differentiation is characterized by growth arrest and accumulation of cells in G0/G1. 13 The role of the Cip/Kip family in the cell cycle exit of terminally differentiating cells has been recently described during erythroid differentiation of MEL cells. 37 Further studies will be necessary to clarify why the absence of Bcl-X L does not affect the cell cycle withdrawal in differentiating leukemic cells.
Here, we found that Bcl-X L antisense inhibited the production of heme but not the synthesis of ␣-and ␤-globin after DMSO induction of MEL cells. Moreover, treatment of DMSO-induced MEL cells expressing Bcl-X L antisense with exogenous hemin overcame the block in hemoglobin synthesis, suggesting that they have a defect in the induction of heme biosynthesis. These results show that Bcl-X L has an essential role in heme synthesis during terminal erythroid differentiation of MEL cells. Heme biosynthesis is carried out by a series of enzymes which are activated during MEL differentiation. 19 Increases in the activities of heme pathway enzymes occur sequentially in the order they appear in the heme biosynthetic pathway, and mRNAs for these enzymes accumulate before ␣-and ␤-globin mRNAs when MEL cells are induced by DMSO. 26 As previously reported, DMSO treatment in MEL cells restores the activity of GATA-1 that is essential for expression of erythroid-specific genes such as globin and heme biosynthetic enzyme genes. 38 Because ␣-and ␤-globin mRNAs are induced in MEL cells expressing Bcl-X L antisense when treated by DMSO, it is unlikely that the defect in heme synthesis was due to an absence of heme pathway enzymes. Therefore, our results suggest that Bcl-X L is required for a late step of heme synthesis.
Our observation that Bcl-X L accumulated in mitochondria during DMSO-induced MEL differentiation is compatible with a role in heme biosynthesis. Indeed, mitochondria participate in many essential functions during erythroid differentiation, including heme biosynthesis. The first and the 3 last steps of heme synthesis occur in the mitochondria. 39 Little is known about how biosynthetic intermediates are shuttled across mitochondrial membranes. A novel mitochondrial transporter, ABC-mitochondrial erythroid (ABC-me), was recently described. 40 This protein is induced during erythroid maturation in cell lines and primary hematopoietic cells. ABC-me is believed to mediate critical mitochondrial transport functions related to heme biosynthesis. Since both Bcl-X L and ABC-me are induced during erythroid MEL differentiation and are located in mitochondrial membranes, it is possible that they interact and cooperate, across mitochondrial membranes, in the transport of substrates that are required for heme biosynthesis. ABC-me is a member of the ATP-binding cassette which depends on ATP for its function. It was recently described that when Bcl-X L resides in the outer mitochondrial membrane (OMM), it appears to maintain mitochondrial ATP/ADP exchange across the inner membrane by facilitating OMM permeability to adenine nucleotides. 41, 42 Then it is possible that Bcl-X L may allow MEL cells to maintain sufficient mitochondrial ATP/ADP exchange to provide ATP for ABC-me during terminal erythroid differentiation.
In summary, these studies provide evidence that Bcl-X L has a fundamental role in terminal erythroid differentiation. It appears to be required in heme biosynthesis independently of its antiapoptotic function. The effect of Bcl-X L in heme synthesis seems to be related to its mitochondrial localization. It remains to be determined how Bcl-X L is involved in heme synthesis and whether its dual function, survival and heme formation, found in MEL cells is also present in normal erythroid maturation.
